Please login to the form below

Not currently logged in
Email:
Password:

Therapeutic vaccines

This page shows the latest Therapeutic vaccines news and features for those working in and with pharma, biotech and healthcare.

EU secures 405 million doses of CureVac’s COVID-19 vaccine

EU secures 405 million doses of CureVac’s COVID-19 vaccine

CureVac’s candidate, like other investigational vaccines from Pfizer and BioNTech and Moderna, uses mRNA technology, which is a relatively new research area. ... The hope is that by using mRNA technology to develop vaccines and therapeutic treatments,

Latest news

More from news
Approximately 0 fully matching, plus 27 partially matching documents found.

Latest Intelligence

  • Switzerland: a life sciences hub Switzerland: a life sciences hub

    A partial revision to the Swiss Patents Act and its implementing provisions came into force on 1 January 2019, together with an ordinary revision of the Therapeutic Products Act. ... For example, over the last five years, Lundbeck acquired Prexton

  • Biotech profile: Tom Evans, CEO, Vaccitech.

    You have a broad pipeline of candidates, including therapeutic vaccines, such as your vaccine for prostate cancer in phase 1. ... How big a role do you think therapeutic vaccines will play in future cancer treatment?

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    Researchers are now trying to identify biomarker-based subgroups and drug combinations to try to improve therapeutic outcomes for patients. ... Vaccines. While the first therapeutic cancer vaccines have reached the market, eg Dendreon’s Provenge and

  • Deal Watch table for January 2015 Deal Watch table for January 2015

    Exclusive licence. 522. AC Immune/ Janssen. To develop and commercialise therapeutic anti-Tau vaccines [ACI35, P1] for the treatment of Alzheimer's disease. ... 3 year research collaboration and exclusive licence. 509. Neuropore Therapies/UCB. To develop

  • Pharma deals during July 2014 Pharma deals during July 2014

    The deal brings to Mylan a portfolio of over 100 specialty and branded generic products in five major therapeutic areas (cardio-metabolic, gastrointestinal, anti-infective/respiratory, CNS/pain and women's ... Baxter forecasts that its revenues from

More from intelligence
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Visformatics (VISFO)

A team of strategic decision specialists with over 30+ years in the pharma space, we give you confidence through experience....

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....